Metastasis from Malignant Tumor of Liver clinical trials at UCSF
1 research study open to eligible people
Metastasis from a malignant liver tumor means cancer has spread beyond the liver. At UCSF, researchers are testing a treatment called NBTXR3 with radiotherapy for advanced cancers. The trial includes patients who are also undergoing anti-PD-1 therapy.
Showing trials for
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
open to eligible people ages 18 years and up
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
San Francisco, California and other locations
Our lead scientists for Metastasis from Malignant Tumor of Liver research studies include Jason Chan.
Last updated: